citalopram has been researched along with Schizophrenia in 46 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a 52 week, placebo-controlled add-on trial of citalopram in patients with FES who did not meet criteria for major depression to determine whether maintenance therapy with citalopram would improve outcomes by preventing or improving negative and depressive symptoms." | 9.30 | Citalopram in first episode schizophrenia: The DECIFER trial. ( Ardekani, BA; Bello, I; Cather, C; Diminich, E; Fan, X; Freudenreich, O; Goff, DC; Holt, D; Li, C; Tang, Y; Troxel, A; Wang, J; Worthington, M; Wu, R; Zeng, B; Zhao, J, 2019) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 9.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "Subsyndromal symptoms of depression in middle aged and older patients with schizophrenia responded to treatment with citalopram with lessening of depressive symptoms and improved functioning and quality of life." | 9.14 | Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. ( Fellows, I; Golshan, S; Jeste, DV; Kasckow, JW; Lehman, D; Mohamed, S; Solorzano, E; Zisook, S, 2009) |
| "To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms." | 9.14 | Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. ( Fellows, I; Golshan, S; Kasckow, JW; Lanouette, NM; Mohamed, S; Rao, S; Vahia, I; Zisook, S, 2010) |
| "We conducted a 10-week single-blind trial of citalopram (20-40 mg/day) vs no citalopram augmentation in 19 middle-aged and elderly patients with schizophrenia hospitalized for more than six of the last 12 months." | 9.09 | Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. ( Carroll, B; Jeste, DV; Kasckow, JW; Mohamed, S; Thallasinos, A; Zisook, S, 2001) |
| " The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)." | 9.08 | Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997) |
| "When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied." | 8.88 | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 7.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects." | 7.85 | Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. ( Górska, A; Gołembiowska, K; Jurczak, A; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z, 2017) |
| "Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia." | 6.75 | Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 5.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| " We conducted a 52 week, placebo-controlled add-on trial of citalopram in patients with FES who did not meet criteria for major depression to determine whether maintenance therapy with citalopram would improve outcomes by preventing or improving negative and depressive symptoms." | 5.30 | Citalopram in first episode schizophrenia: The DECIFER trial. ( Ardekani, BA; Bello, I; Cather, C; Diminich, E; Fan, X; Freudenreich, O; Goff, DC; Holt, D; Li, C; Tang, Y; Troxel, A; Wang, J; Worthington, M; Wu, R; Zeng, B; Zhao, J, 2019) |
| "To establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia." | 5.22 | Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. ( Baldwin, D; Barnes, TR; Costelloe, C; Craig, TK; Crawford, M; Geddes, J; Ismail, S; Keown, P; Killaspy, H; Kiss, N; Kumar, M; Leeson, VC; Lewis, G; Lewis, S; Osborn, D; Pathak, R; Paton, C; Simon, J; Taylor, S, 2016) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 5.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "Subsyndromal symptoms of depression in middle aged and older patients with schizophrenia responded to treatment with citalopram with lessening of depressive symptoms and improved functioning and quality of life." | 5.14 | Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. ( Fellows, I; Golshan, S; Jeste, DV; Kasckow, JW; Lehman, D; Mohamed, S; Solorzano, E; Zisook, S, 2009) |
| "Citalopram augmentation of antipsychotic treatment in middle aged and older patients with schizophrenia and subsyndromal depression appears to improve social and mental health functioning as well as quality of life." | 5.14 | Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. ( Fellows, I; Golshan, S; Kasckow, J; Lanouette, N; Patterson, T; Solorzano, E; Zisook, S, 2010) |
| "To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms." | 5.14 | Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. ( Fellows, I; Golshan, S; Kasckow, JW; Lanouette, NM; Mohamed, S; Rao, S; Vahia, I; Zisook, S, 2010) |
| "The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression (SSD) treated citalopram with depressive symptoms and other outcomes." | 5.14 | Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. ( Fellows, I; Golshan, S; Kasckow, J; Meeks, T; Solorzano, E; Zisook, S, 2010) |
| "We conducted a 10-week single-blind trial of citalopram (20-40 mg/day) vs no citalopram augmentation in 19 middle-aged and elderly patients with schizophrenia hospitalized for more than six of the last 12 months." | 5.09 | Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. ( Carroll, B; Jeste, DV; Kasckow, JW; Mohamed, S; Thallasinos, A; Zisook, S, 2001) |
| " The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)." | 5.08 | Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997) |
| "Our results provide tentative very low quality evidence that compared to placebo, NRIs (specifically reboxetine) may have a benefit on the negative symptoms of schizophrenia." | 4.98 | Selective noradrenaline reuptake inhibitors for schizophrenia. ( Horder, J; Matthews, PRL; Pearce, M, 2018) |
| " They also suggest that lithium for comorbid bipolar disorder, escitalopram for comorbid anxiety disorders, and the addition of CBT to standard drug treatment for comorbid schizophrenia may be effective." | 4.93 | Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research. ( Dowling, NA; Lorains, FK; Merkouris, SS, 2016) |
| "When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied." | 4.88 | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 3.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects." | 3.85 | Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. ( Górska, A; Gołembiowska, K; Jurczak, A; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z, 2017) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| "While treatment of depression in major depressive disorder may partially ameliorate cognitive deficits, the cognitive effects of antidepressant medications in patients with schizophrenia or schizoaffective disorder and SSD are unknown." | 2.77 | Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? ( Dawes, SE; Golshan, S; Kasckow, J; Meeks, T; Mohamed, S; Palmer, BW; Zisook, S, 2012) |
| "Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia." | 2.75 | Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 1.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Ziprasidone was tested as a positive control." | 1.33 | Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. ( Andersen, MP; Hogg, S; Pouzet, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (15.22) | 18.2507 |
| 2000's | 13 (28.26) | 29.6817 |
| 2010's | 23 (50.00) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, W | 2 |
| Marx, J | 2 |
| Zingman, M | 1 |
| Li, Y | 2 |
| Petkova, E | 1 |
| Blessing, E | 2 |
| Ardekani, B | 1 |
| Sakalli Kani, A | 1 |
| Cather, C | 3 |
| Freudenreich, O | 3 |
| Holt, D | 3 |
| Zhao, J | 3 |
| Wang, J | 3 |
| Goff, DC | 3 |
| Fischer, CE | 3 |
| Namasivayam, A | 3 |
| Crawford-Holland, L | 3 |
| Hakobyan, N | 3 |
| Schweizer, TA | 3 |
| Munoz, DG | 3 |
| Pollock, BG | 3 |
| Li, C | 2 |
| Ardekani, BA | 2 |
| Hart, KL | 1 |
| Bello, I | 2 |
| Diminich, ED | 1 |
| Tang, Y | 2 |
| Worthington, M | 2 |
| Zeng, B | 2 |
| Wu, R | 2 |
| Fan, X | 2 |
| Troxel, A | 2 |
| Matthews, PRL | 1 |
| Horder, J | 1 |
| Pearce, M | 1 |
| Ding, N | 1 |
| Li, Z | 1 |
| Liu, Z | 1 |
| Rogóż, Z | 2 |
| Wąsik, A | 1 |
| Lorenc-Koci, E | 1 |
| Diminich, E | 1 |
| Rubin-Kahana, DS | 1 |
| Shelef, A | 1 |
| Weizman, A | 3 |
| Gothelf, D | 1 |
| Timinski, I | 1 |
| Spivak, B | 2 |
| Stryjer, R | 2 |
| Hinkelmann, K | 1 |
| Yassouridis, A | 1 |
| Kellner, M | 1 |
| Jahn, H | 1 |
| Wiedemann, K | 1 |
| Raedler, TJ | 1 |
| Tsai, CH | 1 |
| Chen, TT | 1 |
| Huang, WL | 1 |
| Usall, J | 1 |
| López-Carrilero, R | 1 |
| Iniesta, R | 1 |
| Roca, M | 1 |
| Caballero, M | 1 |
| Rodriguez-Jimenez, R | 1 |
| Oliveira, C | 1 |
| Bernardo, M | 1 |
| Corripio, I | 1 |
| Sindreu, SD | 1 |
| González Piqueras, JC | 1 |
| Felipe, AE | 1 |
| Fernandez de Corres, B | 1 |
| Ibáñez, A | 1 |
| Huerta, R | 1 |
| Dowling, NA | 1 |
| Merkouris, SS | 1 |
| Lorains, FK | 1 |
| Barnes, TR | 1 |
| Leeson, VC | 1 |
| Paton, C | 1 |
| Costelloe, C | 1 |
| Simon, J | 1 |
| Kiss, N | 1 |
| Osborn, D | 1 |
| Killaspy, H | 1 |
| Craig, TK | 1 |
| Lewis, S | 1 |
| Keown, P | 1 |
| Ismail, S | 1 |
| Crawford, M | 1 |
| Baldwin, D | 1 |
| Lewis, G | 1 |
| Geddes, J | 1 |
| Kumar, M | 1 |
| Pathak, R | 1 |
| Taylor, S | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Tao, C | 1 |
| Yan, W | 1 |
| Lu, X | 1 |
| Kamińska, K | 1 |
| Noworyta-Sokołowska, K | 1 |
| Jurczak, A | 1 |
| Górska, A | 1 |
| Gołembiowska, K | 1 |
| Zisook, S | 8 |
| Kasckow, JW | 4 |
| Golshan, S | 6 |
| Fellows, I | 5 |
| Solorzano, E | 4 |
| Lehman, D | 2 |
| Mohamed, S | 6 |
| Jeste, DV | 2 |
| Wienberg, M | 1 |
| Glenthoj, BY | 1 |
| Jensen, KS | 1 |
| Oranje, B | 1 |
| Kasckow, J | 4 |
| Lanouette, N | 1 |
| Patterson, T | 1 |
| Lanouette, NM | 1 |
| Vahia, I | 1 |
| Rao, S | 1 |
| Iancu, I | 1 |
| Tschernihovsky, E | 1 |
| Bodner, E | 1 |
| Piconne, AS | 1 |
| Lowengrub, K | 1 |
| Meeks, T | 2 |
| Osatuke, K | 1 |
| Reid, M | 1 |
| Stiles, WB | 1 |
| Sommer, IE | 1 |
| Begemann, MJ | 1 |
| Temmerman, A | 1 |
| Leucht, S | 1 |
| Dawes, SE | 1 |
| Palmer, BW | 2 |
| Sparkman, NL | 1 |
| Li, M | 1 |
| Dambinsky, Y | 1 |
| Timinsky, I | 1 |
| Green, T | 1 |
| Kotler, M | 1 |
| Kordon, A | 1 |
| Broocks, A | 1 |
| Hohagen, F | 1 |
| Pouzet, B | 1 |
| Andersen, MP | 1 |
| Hogg, S | 1 |
| Sievers, M | 1 |
| Sato, T | 1 |
| Möller, HJ | 1 |
| Bottlender, R | 1 |
| Friedman, JI | 1 |
| Ocampo, R | 1 |
| Elbaz, Z | 1 |
| Parrella, M | 1 |
| White, L | 1 |
| Bowler, S | 1 |
| Davis, KL | 1 |
| Harvey, PD | 1 |
| Barkan, T | 1 |
| Peled, A | 1 |
| Modai, I | 1 |
| Rehavi, M | 1 |
| Ziegenbein, M | 1 |
| Kropp, S | 1 |
| Hillemacher, T | 1 |
| Bleich, S | 1 |
| Lindberg, N | 1 |
| Tani, P | 1 |
| Takala, P | 1 |
| Sailas, E | 1 |
| Putkonen, H | 1 |
| Eronen, M | 1 |
| Virkkunen, M | 2 |
| Padala, PR | 1 |
| Sadiq, HJ | 1 |
| Padala, KP | 1 |
| Montross, L | 1 |
| Patterson, TL | 1 |
| Haukka, J | 1 |
| Tiihonen, J | 2 |
| Härkänen, T | 1 |
| Lönnqvist, J | 1 |
| Dollfus, S | 1 |
| Larmurier-Montagne, A | 1 |
| Razafimandimby, A | 1 |
| Allio, G | 1 |
| Membrey, JM | 1 |
| Delcroix, N | 1 |
| Etard, O | 1 |
| Vartiainen, H | 1 |
| Putkonen, A | 1 |
| Koponen, H | 1 |
| Hakola, P | 1 |
| Lehto, H | 4 |
| Oretti, RG | 1 |
| Spurlock, G | 1 |
| Buckland, PR | 1 |
| McGuffin, P | 1 |
| Salokangas, RK | 3 |
| Saarijärvi, S | 3 |
| Taiminen, T | 2 |
| Kallioniemi, H | 1 |
| Niemi, H | 3 |
| Tuominen, J | 1 |
| Ahola, V | 3 |
| Syvälahti, E | 3 |
| Taiminen, TJ | 1 |
| Soares, JC | 1 |
| Gershon, S | 1 |
| Taylor, D | 1 |
| Ellison, Z | 1 |
| Ementon Shaw, L | 1 |
| Wickham, H | 1 |
| Murray, R | 1 |
| Thallasinos, A | 1 |
| Carroll, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia[NCT01300364] | Phase 4 | 249 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Citalopram Augmentation in Older Patients With Schizophrenia[NCT00047450] | 212 participants (Actual) | Interventional | 2001-09-30 | Completed | |||
| Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial[NCT02533232] | Phase 1 | 60 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | ||
| Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia[NCT00148447] | Phase 3 | 40 participants | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for citalopram and Schizophrenia
| Article | Year |
|---|---|
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Selective noradrenaline reuptake inhibitors for schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Citalopram; Cognition; Humans; Morph | 2018 |
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research.
Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar | 2016 |
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Citalopram; Clozapine; Dioxoles; Double-Blind | 2012 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
Therapeutic targets in late-life psychoses: review of concepts and critical issues.
Topics: Affective Disorders, Psychotic; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Benzodiazepin | 1997 |
23 trials available for citalopram and Schizophrenia
| Article | Year |
|---|---|
Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia.
Topics: China; Citalopram; Hippocampus; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Schizophren | 2023 |
Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients - A randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Citalopram; Double-Blind Method; Drug Synergism; Drug Therapy, Combinat | 2018 |
Citalopram in first episode schizophrenia: The DECIFER trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; | 2019 |
No effects of antidepressants on negative symptoms in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Analysis of Variance; Antidepressive Agents; Antipsycho | 2013 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double- | 2014 |
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Cost-Benefit Anal | 2016 |
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Citalopram; Diagnostic and Statistical Manual of | 2009 |
A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers.
Topics: Acoustic Stimulation; Adult; Anxiety Disorders; Blood Pressure; Citalopram; Cross-Over Studies; Doub | 2010 |
Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Citalopram; Depressive Disorder; Female; Humans; M | 2010 |
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depression; | 2010 |
Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.
Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Human | 2010 |
Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depression; | 2010 |
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Awareness | 2011 |
Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?
Topics: Adult; Aging; Antidepressive Agents; Citalopram; Cognition Disorders; Comorbidity; Depression; Doubl | 2012 |
Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Topics: Adult; Antipsychotic Agents; Anxiety; Citalopram; Compulsive Behavior; Diagnostic and Statistical Ma | 2013 |
The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Citalopram; Cognition; Cross-Over Studies; Double | 2005 |
Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia.
Topics: Age Factors; Chronic Disease; Citalopram; Comorbidity; Depression; Depressive Disorder, Major; Doubl | 2007 |
Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia.
Topics: Adolescent; Adult; Aged; Aggression; Citalopram; Double-Blind Method; Female; Humans; Male; Middle A | 1995 |
Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Citalopram; Dose-Response Relationship, Dr | 1996 |
Effect of smoking on neuroleptics in schizophrenia.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Citalopram; Dose-Response Relationship, Drug; Double | 1997 |
Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia.
Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Humans; Psychiatric Status Rating Scales; S | 1997 |
Co-administration of citalopram and clozapine: effect on plasma clozapine levels.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Cloza | 1998 |
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients.
Topics: Aged; Antipsychotic Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; | 2001 |
17 other studies available for citalopram and Schizophrenia
| Article | Year |
|---|---|
Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial.
Topics: Antipsychotic Agents; Citalopram; Hippocampus; Humans; Magnetic Resonance Imaging; Schizophrenia | 2021 |
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Anim | 2018 |
The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.
Topics: Adult; Antipsychotic Agents; Citalopram; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Dis | 2019 |
Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia.
Topics: Aripiprazole; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quino | 2014 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpin | 2016 |
Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects.
Topics: Animals; Antipsychotic Agents; Citalopram; Dopamine; Drug Therapy, Combination; Male; Nucleus Accumb | 2017 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psycho | 2012 |
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Bupropion; Cital | 2005 |
Obsessive-compulsive disorder (OCD) with psychotic symptoms and response to treatment with SSRI.
Topics: Adult; Behavior Therapy; Citalopram; Drug Administration Schedule; Female; Humans; Obsessive-Compuls | 2005 |
Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Citalopram; Female; Humans; Lymphocytes; Male; Middle | 2006 |
Genetic predisposition to neuroleptic malignant syndrome in siblings.
Topics: Adult; Antipsychotic Agents; Citalopram; Female; Humans; Male; Neuroleptic Malignant Syndrome; Polym | 2006 |
Increased deep sleep in a medication-free, detoxified female offender with schizophrenia, alcoholism and a history of attempted homicide: effect of concomitant administration of quetiapine and citalopram.
Topics: Adult; Aggression; Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antis | 2006 |
Urinary obstruction with citalopram and aripiprazole combination in an elderly patient.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Citalopram; Drug Therapy, Combination; Humans; Male; Piper | 2006 |
Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Citalopram; Coho | 2008 |
Treatment of auditory hallucinations by combining high-frequency repetitive transcranial magnetic stimulation and functional magnetic resonance imaging.
Topics: Antidepressive Agents; Antipsychotic Agents; Citalopram; Combined Modality Therapy; Comorbidity; Dep | 2008 |
Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Base Sequence; Brain Chemistry; Citalopram; Cl | 1994 |